[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)
date : 3/7/2022
Tags: AMR
![[Case Study] Keisuke Kagami and Mitsuru Sugawara “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis” (AMR Alliance Japan, March 7, 2022)](https://hgpi.org/en/wp-content/uploads/sites/2/amr-case06-top_ENG.jpg)
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital) and Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University) reports a case titled “Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
This is the second of two case studies from AMR Alliance Japan on the usefulness of TDM for antimicrobial stewardship.
Case study 06
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Thrombocytopenia Can be Avoided By Monitoring Linezolid Blood Levels – Enabling Long-Term Linezolid Use for the Successful Treatment of Refractory Pyogenic Spondylodiscitis.”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
Case study 05
Dr. Keisuke Kagami (Department of Pharmacy, Hokkaido University Hospital)
Dr. Mitsuru Sugawara (Department of Pharmacy, Hokkaido University Hospital / Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University)
“Concomitant piperacillin-tazobactam and vancomycin use increases the risk of acute kidney injury.”
日本語
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Policy Recommendations] Establishing an Integrated Care System for Pain from the Perspectives of People with Lived Experience (March 29, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] Participation in an International Survey on Brain Health for Young People “The Next Generation (NextGen) Brain Health Research Program” (July 1, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Japanese Version Release] “Call for Actionable Steps in Response to the Rising Threat of Antimicrobial Resistance (AMR)” (July 3, 2024)
Featured Posts
-
2024-07-01
[Registration Open] Meaningful Involvement Promotion Project Online Expert Meeting “Shaping the Future of Health Policy with People with Lived Experience and Citizens” (July 26, 2024)
-
2024-07-17
[Event Report] Non-partisan Diet Member Briefing – 30-minute Health Policy Update: “Towards Overcoming Kidney Disease: Strengthening Measures Against CKD” (June 7, 2024)
-
2024-07-18
[Registration Open] (Hybrid Format) Kidney Disease Control Promotion Project Public Symposium “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” (August 28, 2024)
-
2024-07-22
[HGPI Policy Column] No. 44 — From the Planetary Health Policy Project, Part 9 “Connecting Climate Minds: the Intersection of Climate Change and Mental Health”
-
2024-07-23
[Registration Open] (Webinar) HGPI Special Seminar “The Emerging Threat of Antifungal Resistance — Considering Infectious Diseases Caused by Mold and Measures to Combat Drug Resistance” (August 23, 2024)